tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI

Denali Therapeutics (DNLI) Cash flow

549 Followers

Denali Therapeutics Cash Flow

DNLI's free cash flow for Q4 2023 was $-100.89M. For the 2023 fiscal year, DNLI's free cash flow was decreased by $-108.38M and operating cash flow was $-98.66M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
$ -270.63M$ -357.99M$ -244.72M$ -211.39M$ 416.15M$ -151.58M
Investing Cash Flow
$ 148.40M$ 249.31M$ -141.39M$ -21.63M$ -623.21M$ 147.71M
Financing Cash Flow
$ 15.33M$ 17.82M$ 310.67M$ 19.35M$ 634.75M$ 6.19M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
$ 331.86M$ 128.68M$ 219.54M$ 294.98M$ 508.64M$ 80.95M
Income Tax Paid Supplemental Data
$ 3.00K$ 3.00K$ 47.00K---
Interest Paid Supplemental Data
------
Issuance Of Capital Stock
--$ 296.21M$ 0.00$ 614.09M$ 0.00
Issuance Of Debt
------
Repayment Of Debt
------
Free Cash Flow
$ -281.50M$ -370.93M$ -262.55M$ -219.89M$ 413.06M$ -169.50M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Denali Therapeutics Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis